Pfizer/BioNTech and Moderna have now both presented Phase III efficacy data on their COVID-19 vaccines which far exceed earlier expectations, and look set to gain emergency use approvals (EUAs) by the end of the year.
In the remarkable sprint to develop a vaccine, all the company chiefs involved have agreed that the race is against...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
